Noncovalent wild-type-sparing inhibitors of EGFR T790M

Cancer Discovery

Volumn 3, Issue 2, 2013, Pages 168-181

  Lee, Ho June ^a,b   Schaefer, Gabriele ^a   Heffron, Timothy P ^a   Shao, Lily ^a   Ye, Xiaofen ^a   Sideris, Steve ^a   Malek, Shiva ^a   Chan, Emily ^a   Merchant, Mark ^a   La, Hank ^a   Ubhayakar, Savita ^a   Yauch, Robert L ^a   Pirazzoli, Valentina ^c   Politi, Katerina ^c,d   Settleman, Jeff ^a,b  

^a GENENTECH INC   (United States)

^b Mas sachusetts General Hospital Cancer Center   (United States)

^c YALE CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6, 7, 12, 13 TETRAHYDRO 13 METHYL 5 OXOINDOLO [2, 3 A] PYRROLO [3, 4 C] CARBAZOLE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LESTAURTINIB; MIDOSTAURIN; UNCLASSIFIED DRUG; WZ 4002;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SCREENING; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ACRYLAMIDES; AMINO ACID SUBSTITUTION; ANIMALS; AREA UNDER CURVE; BASE SEQUENCE; CARBAZOLES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; STAUROSPORINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873902360     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0357     Document Type: Article

References (39)

1. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-31.
2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specifi c inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gam-bacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
4. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefi t-inib therapy. Science 2004;304:1497-500.
7. Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med 2005;2:e377.
8. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
9. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-99.
10. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
11. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefi tinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
12. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6: 834-48.
13. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefi tinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
14. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affi nity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
15. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shi-mamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
16. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac L R, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
17. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83.
18. Jänne PA, Schellens JH, Engelman JA, Eckhardt SG, Millham R, Denis LJ, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8027).
19. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4.
20. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Indentifi cation of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936-41.
21. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-94.
22. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003;63:31-5.
23. Grandage VL, Everington T, Linch DC, Khwaja A. Gö6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with signifi cant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006;135:303-16.
24. Pratz K, Levis M. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma 2008;49:852-63.
25. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008;7:874-9.
26. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71.
27. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefi t-inib. Cancer Res 2007;67:2325-30.
28. Taube E, Jokinen E, Koivunen P, Koivunen JP. A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. Int J Cancer 2012;131:970-9.
29. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech-nol 2011;29:1046-51.
30. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.
31. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
32. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1: 433-43.
33. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003;3:459-69.
34. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92.
35. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
36. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108:3477-83.
37. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92.
38. Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M, et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 2006;95:829-34.
39. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979;63:437-67.